These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 12407139)
1. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. Betriu C; Rodríguez-Avial I; Sánchez BA; Gómez M; Picazo JJ J Antimicrob Chemother; 2002 Nov; 50(5):758-9. PubMed ID: 12407139 [No Abstract] [Full Text] [Related]
2. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Farrell DJ; Sader HS; Jones RN Antimicrob Agents Chemother; 2010 Jun; 54(6):2735-7. PubMed ID: 20368399 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. Insa R; Cercenado E; Goyanes MJ; Morente A; Bouza E J Antimicrob Chemother; 2007 Mar; 59(3):583-5. PubMed ID: 17213264 [No Abstract] [Full Text] [Related]
4. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia. Wei C; Ni W; Cai X; Cui J Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments. Wei C; Ni W; Cai X; Zhao J; Cui J PLoS One; 2016; 11(3):e0152132. PubMed ID: 26999818 [TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014). Pfaller MA; Flamm RK; Duncan LR; Mendes RE; Jones RN; Sader HS Diagn Microbiol Infect Dis; 2017 Jun; 88(2):177-183. PubMed ID: 28341098 [TBL] [Abstract][Full Text] [Related]
7. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368 [TBL] [Abstract][Full Text] [Related]
9. Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations. Hu LF; Gao LP; Ye Y; Chen X; Zhou XT; Yang HF; Liiu YY; Mei Q; Li JB J Chemother; 2014 Oct; 26(5):282-6. PubMed ID: 24588423 [TBL] [Abstract][Full Text] [Related]
10. Susceptibility of 228 non-fermenting gram-negative rods to tigecycline and six other antimicrobial drugs. Gómez-Garcés JL; Aracil B; Gil Y; Burillo A J Chemother; 2009 Jun; 21(3):267-71. PubMed ID: 19567346 [TBL] [Abstract][Full Text] [Related]
11. Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections. Tekçe YT; Erbay A; Cabadak H; Sen S J Chemother; 2012 Jun; 24(3):150-4. PubMed ID: 22759759 [TBL] [Abstract][Full Text] [Related]
12. In vitro combination of tigecycline with other antibiotics in Stenotrophomonas maltophilia isolates. Karamanlıoğlu D; Dizbay M Turk J Med Sci; 2019 Apr; 49(2):683-686. PubMed ID: 30866602 [TBL] [Abstract][Full Text] [Related]
13. Antibiotic susceptibility of sulfamethoxazole-trimethoprim resistant Stenotrophomonas maltophilia strains isolated at a tertiary care centre in Hungary. Juhász E; Pongrácz J; Iván M; Kristóf K Acta Microbiol Immunol Hung; 2015 Sep; 62(3):295-305. PubMed ID: 26551572 [TBL] [Abstract][Full Text] [Related]
14. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Betriu C; Rodríguez-Avial I; Sánchez BA; Gómez M; Alvarez J; Picazo JJ; Antimicrob Agents Chemother; 2002 Mar; 46(3):892-5. PubMed ID: 11850282 [TBL] [Abstract][Full Text] [Related]
15. In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae. Kitzis MD; Ly A; Goldstein FW Antimicrob Agents Chemother; 2004 Jan; 48(1):366-7. PubMed ID: 14693571 [No Abstract] [Full Text] [Related]
16. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. Wu H; Wang JT; Shiau YR; Wang HY; Lauderdale TL; Chang SC; J Microbiol Immunol Infect; 2012 Apr; 45(2):120-6. PubMed ID: 22154599 [TBL] [Abstract][Full Text] [Related]
17. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Boucher HW; Wennersten CB; Eliopoulos GM Antimicrob Agents Chemother; 2000 Aug; 44(8):2225-9. PubMed ID: 10898710 [TBL] [Abstract][Full Text] [Related]
18. Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia. Chong SY; Lee K; Chung HS; Hong SG; Suh Y; Chong Y Microb Drug Resist; 2017 Mar; 23(2):163-168. PubMed ID: 27294684 [TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results? Galles AC; Jones RN; Sader HS J Chemother; 2008 Feb; 20(1):38-42. PubMed ID: 18343741 [TBL] [Abstract][Full Text] [Related]